[go: up one dir, main page]

NO991405L - Belagt partikkelformulering - Google Patents

Belagt partikkelformulering

Info

Publication number
NO991405L
NO991405L NO991405A NO991405A NO991405L NO 991405 L NO991405 L NO 991405L NO 991405 A NO991405 A NO 991405A NO 991405 A NO991405 A NO 991405A NO 991405 L NO991405 L NO 991405L
Authority
NO
Norway
Prior art keywords
coated particle
particle formulation
formulation
preparing
pharmaceutically acceptable
Prior art date
Application number
NO991405A
Other languages
English (en)
Other versions
NO991405D0 (no
Inventor
Tommy Clifford Morris
Hans Joerg Lange
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO991405D0 publication Critical patent/NO991405D0/no
Publication of NO991405L publication Critical patent/NO991405L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Oppfinnelsen tilveiebringe! en farmasøytisk akseptabel fast oral olanzapinformulering og en fremgangsmåte for fremstilling av slik formulering.
NO991405A 1996-09-24 1999-03-23 Belagt partikkelformulering NO991405L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2663396P 1996-09-24 1996-09-24
PCT/US1997/016547 WO1998013027A1 (en) 1996-09-24 1997-09-18 Coated particle formulation

Publications (2)

Publication Number Publication Date
NO991405D0 NO991405D0 (no) 1999-03-23
NO991405L true NO991405L (no) 1999-03-23

Family

ID=21832952

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991405A NO991405L (no) 1996-09-24 1999-03-23 Belagt partikkelformulering

Country Status (21)

Country Link
US (1) US20010020032A1 (no)
EP (1) EP0830858A1 (no)
JP (1) JP2001501207A (no)
KR (1) KR20000048540A (no)
CN (1) CN1230883A (no)
AR (1) AR009802A1 (no)
AU (1) AU719788B2 (no)
BR (1) BR9713215A (no)
CA (1) CA2266448A1 (no)
CO (1) CO4910139A1 (no)
CZ (1) CZ98899A3 (no)
EA (1) EA001610B1 (no)
HU (1) HUP9904065A3 (no)
ID (1) ID21762A (no)
IL (1) IL128845A0 (no)
NO (1) NO991405L (no)
PE (1) PE27899A1 (no)
PL (1) PL332503A1 (no)
TR (1) TR199900651T2 (no)
WO (1) WO1998013027A1 (no)
ZA (1) ZA978517B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
TWI275394B (en) * 2000-01-26 2007-03-11 Asahi Chemical Corp Mizoribin tablet improved with color tone change
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
CA2510319A1 (en) 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
KR101139744B1 (ko) * 2003-04-25 2012-04-26 미쓰비시 타나베 파마 코퍼레이션 알킬렌 디옥시벤젠 유도체 함유 경구 투여용 조성물
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
JP5820874B2 (ja) * 2010-04-30 2015-11-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company N−(4−(2−アミノ−3−クロロピリジン−4−イルオキシ)−3−フルオロフェニル)−4−エトキシ−1−(4−フルオロフェニル)−2−オキソ−1,2−ジヒドロピリジン−3−カルボキサミドを含有する医薬組成物
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USE
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
PH12021553056A1 (en) 2019-06-04 2023-09-11 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
CA2097016A1 (en) * 1992-05-29 1993-11-30 John Fairhurst Pharmaceutical compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine

Also Published As

Publication number Publication date
HUP9904065A2 (hu) 2000-04-28
CA2266448A1 (en) 1998-04-02
BR9713215A (pt) 2000-04-04
EP0830858A1 (en) 1998-03-25
IL128845A0 (en) 2000-01-31
TR199900651T2 (xx) 1999-07-21
ID21762A (id) 1999-07-22
HUP9904065A3 (en) 2001-10-29
NO991405D0 (no) 1999-03-23
AU4423097A (en) 1998-04-17
ZA978517B (en) 1999-03-23
WO1998013027A1 (en) 1998-04-02
AR009802A1 (es) 2000-05-03
JP2001501207A (ja) 2001-01-30
PL332503A1 (en) 1999-09-13
AU719788B2 (en) 2000-05-18
US20010020032A1 (en) 2001-09-06
CN1230883A (zh) 1999-10-06
EA001610B1 (ru) 2001-06-25
CO4910139A1 (es) 2000-04-24
KR20000048540A (ko) 2000-07-25
EA199900331A1 (ru) 2000-04-24
CZ98899A3 (cs) 1999-12-15
PE27899A1 (es) 1999-03-12

Similar Documents

Publication Publication Date Title
NO991405L (no) Belagt partikkelformulering
FI973749A7 (fi) Suun kautta annosteltava 2-metyylitienobentsodiatsepiinivalmiste
HRP980163B1 (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates
MY125467A (en) Olanzapine dihydrate d
AU6853598A (en) Aligner, exposure method using the aligner, and method of manufacture of circuitdevice
AU1053199A (en) Exposure apparatus and method of manufacturing the same, and exposure method
YU15299A (sh) Farmaceutski sastavi
NO910687D0 (no) Fremgangsmaate for fremstilling av et stabilt soetningsmiddel-utleveringssystem og tyggegummi.
IL122485A0 (en) Arylsulfonylaminobenzene derivatives and pharmaceutical compositions containg the same
FI950119A7 (fi) Ulkoinen miehen katetri, sovitin ja menetelmiä sen käyttämiseksi ja valmistamiseksi
ZA969001B (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ZA967546B (en) Pharmaceutical formulation.
HUP9901685A3 (en) Colchicine derivatives, the use thereof and formulations containing them
HUP9702509A3 (en) Derivatives of fused heterocycles substituted on the aminogroup, process for producing them, their use and pharmaceutical compositions thereof
HUP9802408A3 (en) Naphthyl and dihydronaphthyl-derivatives, and pharmaceutical compositions, containing them
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
IS5062A (is) Lyfjablöndur sem innihalda afleiður N-súlfonýlindólíns
ES2172182T3 (es) Composiciones farmaceuticas que comprenden cefuroxima axetil.
AU8040991A (en) Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
AU1671197A (en) Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
ZA972708B (en) Pharmaceutical compositions and methods for the manufacture thereof.
AU697041B2 (en) Mannich base derivatives, and the production and uses thereof
IL118002A (en) Insecticide formulations and process for the manufacture thereof
GB2325229B (en) 2,3-Disubstituted cyclopentanone derivatives, process for producing the same, and medicinal use thereof
JO1909B1 (en) Composition of 2-methylthenio-benzodiazepine oral

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application